Therapeutic good administration

Sagar Savale
Sagar SavaleTechnology Transfer Scientist [sks747202@gmail.com]
Therapeutic Good Administration
Australia [TGA]
1
Mr. Sagar Kishor SavaleMr. Sagar Kishor Savale
Department of Pharmaceutics
avengersagar16@gmail.com
2015-016
Department of Pharmacy (Pharmaceutics)Department of Pharmacy (Pharmaceutics) || Sagar savaleSagar savale
04/28/16 SAGAR SAVALE
CONTENTS:
 HISTORY
 TGA STRUCTURE
 THERAPEUTIC GOODS ACT 1989
 REGULATION OF MEDICINE
 AUSTRELIAN REGISTER FOR THERAPEUTIC GOOD
 REGISTRATION OF MEDICINE
 THERAPEUTIC CLAIMS
 STANDARD FOR THE UNIFORM SCHDULING OF DRUG & POISONS
 COUNTERFEIT DRUGS
204/28/16 SAGAR SAVALE
HISTORY-
The Evolution of Therapeutic goods Administration in Australia can be
broadly segmented into following periods.
1)The period until 1938 -During this period there was an increasing
number of medicines appearing in an unregulated market, with many
products regarded as ‘quack’ medicine.
2)1939-1961:NHMRC developing a more uniform national approach
to labeling and standards need for independent laboratory testing.
The government moved to regulate the standards for medicines for
good quality. The National Biological Standards Laboratory was
established to independently test medicines on the Australian market
and regulate their manufacture.
3)1962-1988: Pre-market assessment of quality, safety and efficacy
evolved and finally was integrated into National system of
integration of therapeutic good regulation and establishment of TGA.
4)1989-2007:The national system TGA continued to mature into an
internationally harmonized regulatory system with increasing
globalization.
304/28/16 SAGAR SAVALE
INTRODUCTION OF TGA:
• The Therapeutic Goods Administration (TGA) is a unit of the
Australian Government Department of Health and Ageing.
• The TGA monitoring activities to ensure therapeutic goods
available in Australia are of an acceptable standard.
• The Australian community expects that medicines and medical
devices in the marketplace are safe and of high quality, and of a
standard at least equal to that of comparable countries.
• The regulatory framework within which the TGA operates is
based on a risk management approach. It is designed to ensure
public health and safety.
• It is beneficial for both consumers and industry
• In undertaking its responsibility, the TGA has developed a
constructive partnership with industry at the same time freeing
industry from any unnecessary regulatory burden and minimizing
the cost of medicines.
404/28/16 SAGAR SAVALE
TGA STRUCTRE-
• The TGA Regulatory offices are grouped into –
1. Market Authorisation Group
2. Monitoring and Compliance Group
3. Regulatory Support Group
• TGA Executive
• The TGA Executive has overall responsibility for the
management of the TGA's regulatory activities.
1.Market Authorization Group
• The Market Authorization Group is responsible for the
evaluation and authorization of therapeutic goods to ensure
they meet appropriate standards of quality, safety and
efficacy.
504/28/16 SAGAR SAVALE
2.Monitoring and Compliance Group-
• The Monitoring and Compliance Group is responsible for
monitoring of therapeutic goods on the Australian market to
ensure that they comply with required standards of quality,
safety, efficacy .
3.Regulatory Support Group
• The Regulatory Support Group provides the business systems
and support services that help the TGA to undertake its
regulatory responsibilities.
• Office of Regulatory Integrity
• The Office of Regulatory Integrity functions as an internal
auditor of regulatory activity and advises the TGA Executive on
the appropriate operations.
604/28/16 SAGAR SAVALE
Therapeutic Goods Act 1989
• Therapeutic Goods Act 1989, is to provide a national framework
for the regulation of therapeutic goods in Australia to ensure
the
Quality, Safety and Efficacy of medicines
Ensure the quality, safety and performance of medical devices.
• The Act is a Commonwealth Act that provides a uniform national
system of controls over therapeutic goods.
• facilitating trade between the States/Territories and benefiting
for both consumers and industry.
• Essentially therapeutic goods must be entered on the Australian
Register of Therapeutic Goods (ARTG) before they can be
supplied in Australia.
• The ARTG is a computer database of information about
therapeutic goods for human use approved for supply in, or
exported from Australia. 704/28/16 SAGAR SAVALE
• It also details the requirements for listing or registering
medicines in the Australian Register of Therapeutic Goods.
• The act sets out the legal requirement for the import , export,
and supply of medicines in Australia.
• The Therapeutic Goods Act sets out requirements for
manufacturing, advertising and labeling of medicines in Australia.
• It also establishes controls relating to the advertising of
therapeutic goods which aim to minimize the risk of misuse of
such products arising out of, for example, misrepresentation or
misunderstanding about the uses of the goods.
• It offers the advantage for consumers and healthcare
professionals to be able to have confidence in the standard of
ready-made proprietary therapeutic goods which they use or
prescribe.
804/28/16 SAGAR SAVALE
Does the Act apply to your product?
You will need to comply with the Act if your product is a
'therapeutic good'. 'Therapeutic goods' may be:
• Medicines, or
• Medical devices
• Some products will be classified as a medicine or as a
food or cosmetic depending on how that particular
product fits with the criteria set out in the Act.
904/28/16 SAGAR SAVALE
What are 'therapeutic goods'?
A 'therapeutic good is broadly defined as a good which is
represented in any way to be, or is likely to be taken to
be, for therapeutic use under section 7 of the Act.
• Therapeutic good is a product for use in humans that is
used in, or in connection with:-
• Preventing, diagnosing, curing a disease, defect or injury
OR
• Influencing, inhibiting or modifying a physiological
process OR
• Testing the susceptibility of persons to a disease OR
• Influencing, controlling or preventing conception OR
• Testing for pregnancy
1004/28/16 SAGAR SAVALE
Is it a medicine or food?
• Products for oral consumption are regulated as either
foods or therapeutic goods
• Products which may fit within the definition of either a
food or a medicine are referred to a joint TGA/Food
Standards Australia committee which recommends
whether the goods should be regulated as a therapeutic
good or as food
• A product's principal use is of primary consideration
when determining whether it is a food or a medicine
• The presentation of a product can help to determine
whether it will be treated as a food or a medicine. For
example, a clove of garlic is a food. However, if it is
concentrated and marketed in capsule form with claims
that it can be used to relieve cold and 'flu symptoms it
will be treated as a medicine 1104/28/16 SAGAR SAVALE
Is it a medicine or a cosmetic?
• One of the main factors in determining whether a
product is a cosmetic or a medicine is the claims made
about the product.
• For example, moisturizers which contain a sun
screening agent as a secondary component and have a
stated therapeutic purpose (e.g. 'helps protect skin
from the damaging effects of UV radiation') are
medicine
• Note that the Trade Practices Act 1974 also operates in
this area and influences what may or may not be
claimed.
• The Cosmetic Claims Guidelines provides further
guidance on the difference between cosmetic and
therapeutic claims
1204/28/16 SAGAR SAVALE
Regulation of Medicines
• The Therapeutic Goods Administration overall control
the of supply of medicines in Australia is exercised
through following main processes:
• 1. Pre-market evaluation and approval of medicines
intended for supply in Australia
• 2. Licensing of manufacturers in accordance with
international standards under Good Manufacturing
Practice
• 3. Post-market monitoring, through sampling, adverse
event reporting, surveillance activities, and response to
public inquiries
• 4. maintenance and monitoring of the systems for
registering and listing of medicines
1304/28/16 SAGAR SAVALE
Pre-Market Assessment-
• Drugs are required to undergo an assessment before it can
be listed or registered.
• Number of factors are taken into consideration including:
• The toxicity of the ingredients.
• The dosage form of the medicine
• whether the medicine is indicated for a serious form of a
disease, or disorder, or for the treatment, cure, prevention of
a disease or disorder
• whether the drug is likely to result in significant side effects,
including interactions with other medicines; and
• The degree of control over a medicine is directly related to
the risk level of that medicine. Therefore, registered
medicines are required to undergo a more rigorous
assessment than listed medicines
1404/28/16 SAGAR SAVALE
• Manufacturing Requirements- Australian manufacturers
of medicines must be licensed under the Therapeutic
Goods Act 1989. Their manufacturing processes must
comply with principles of Good Manufacturing Practice.
The aim of licensing is to protect public health by ensuring
that medicines meet definable standards of quality
assurance and are manufactured in conditions which are
clean and free of contaminants.
• Licensing of Manufacturers
Applications for a manufacturing license are assessed
through an inspection of the manufacturing premises.
Auditors from the TGA conduct audits of manufacturing
premises and a license is issued only after all the
requirements have been met. Audits are conducted
before a license is issued, And at regular intervals after the
license has been granted generally every 15 to 24 months.
1504/28/16 SAGAR SAVALE
Post-Market Vigilance-
In Australia, post-market vigilance activities include the
following:
• Conducting laboratory testing of products on the market and
if necessary, conducting recalls of deficient medicines.
• According to the TGA, these activities are conducted
regularly and in response to problem reports received.
• Adverse Drug Event Reporting- The Adverse Drug Reactions
Advisory Committee(ADRAC) is responsible for monitoring
drug safety in the post-marketing phase.
• This involves checking the report of adverse reaction of the
drug, investigating problems by the Therapeutic Goods
Administration and relevant committees to ensure that
medicines are of an acceptable standard.
1604/28/16 SAGAR SAVALE
• Making the decision as to whether further information such
as clinical or laboratory testing results are required.
• The reports are then entered into a database and reviewed
by the ADRAC which would provide advice on the
appropriate responses to adverse reactions such as a recall
of deficient medicines to the relevant authorities e.g.
Australian Drug Evaluation Committee for pharmaceutical
products, Medicines Evaluation Committee for over-the-
counter medicines, Office of Complementary Medicines of
the T G A for complementary medicines, etc.
• Recall of Medicines-
• A recall is a permanent removal of deficient medicines from
the market. Most recalls are conducted on a voluntary
basis. However, the recall procedures are carried by
Therapeutic Goods Act 1989 and the Trade Practices Act
1974. 1704/28/16 SAGAR SAVALE
• There are four levels of recall: wholesale, hospital, retail and
consumer.
• A wholesale level refers to a recall from state purchasing
authorities.
• A hospital level recall includes a whole sale level recall and
recalls from nursing homes, hospital pharmacies, etc.
• A retail level recall includes a wholesale level recall, a
hospital level recall and recalls from retail pharmacists,
medical practitioners, retail outlets, etc.
• A consumer level recall includes a whole sale level recall, a
hospital level recall, a retail level recall and recalls from
patients and other consumers.
1804/28/16 SAGAR SAVALE
REGULATION OF MEDICINE IN AUSTRELIA
In Australia, medicines can be classified as
1) Registered medicines or
2) Listed medicines, depending on their ingredients and claims
made.
Registered medicines can be further classified as-
1)Non-prescription (low risk) registered medicines and as
2) Prescription (high risk) registered medicines.
All medicines which are for export only are considered as
listed medicines.
• Registered medicines are of higher risk than listed
medicines, therefore, the degree of control imposed on
registered medicines is higher than that of listed medicines;
• Registered medicines are evaluated for safety, quality and
efficacy while listed medicines are evaluated for safety and
quality only. 1904/28/16 SAGAR SAVALE
2004/28/16 SAGAR SAVALE
• Austrelian Register for Therapeutic Good
• The Australian Register of Therapeutic Goods is a
database of information about therapeutic goods which
are approved for supply in or export from Australia.
• Registered medicines in the Australian Register of
Therapeutic Goods are of higher risk than listed
medicines.
• Therefore the level of assessment and the degree of
regulation which registered medicines undergo are also
more rigorous and detailed.
• The sponsors of registered medicines are required to
provide comprehensive safety, quality and efficacy data.
• sponsors of listed medicines are required to provide data
on safety and quality only.
• Diagram shows the risk relationship between the various
types of medicines registered or listed in the ARTG.
2104/28/16 SAGAR SAVALE
04/28/16 SAGAR SAVALE 22
Listed Medicines (low-risk)-
• A listed medicine is one that contains chemical, biological, or
herbal ingredients that are well-known and considered safe to
the user such ingredients usually have a long history of use.
• They are considered as low-risk, their ingredients appear in the
TGA’s approved list of substances.
• Listed medicines do not contain substances which are scheduled
in the Standard for Uniform Scheduling of Drugs and Poisons.
• The therapeutic claim of medicine relates to health
maintenance, health enhancement, or non-serious, self-limiting
conditions.
• Listed medicines are assessed by the TGA for quality and safety
but not efficacy. This means that the TGA has not evaluated them
individually to see if they work.
2304/28/16 SAGAR SAVALE
• Listed medicines are low risk medicines and they may only
contain ingredients which are listed in the Australian
Register of Therapeutic Goods.
• For the evaluation process, sponsors are allowed to self-
assess the products, i.e. the products are assessed by
sponsors against standards defined by the Therapeutic
Goods Administration.
• The assessment is then subject to a simple 'eligibility review'
by the Therapeutic Goods Administration for compliance
with certain basic safety and quality parameters.
• If the assessment passes the 'eligibility review', the sponsor
receives a confirmation letter from the Therapeutic Goods
Administration and the medicine can be listed in the
Australian Register of Therapeutic Goods
2404/28/16 SAGAR SAVALE
LISTING OF MEDICINE IN ARTG
04/28/16 SAGAR SAVALE 25
REGISTERED MEDICINE
• Registered medicines can be high risk products or low risk
products.
• They can be classified either as non-prescription (low risk)
registered medicines or as prescription (high risk)
registered medicines.
• Medicines having a higher level of risk must be registered
(not listed).
• The degree of assessment and regulation they undergo is
rigorous and detailed, with sponsors being required to
provide comprehensive safety, quality and efficacy data.
• All registered medicines must display an AUST R number on
the label as proof of registration are evaluated as either
'high risk' or 'low risk' registered
2604/28/16 SAGAR SAVALE
• In assessing the level of 'risk', factors such as the strength
of a product, side effects, potential harm through
prolonged use, toxicity, and the seriousness of the
medical condition for which the product is intended to be
used are taken into account.
Non-Prescription (Low Risk) Registered Medicines:
• The purchase of non-prescription (low risk) registered
medicines does not require a doctor's prescription.
Examples of non-prescription (low risk) registered
medicines are over-the-counter medicines such as
analgesics, cough/cold preparations.
Prescription (High Risk) Registered Medicines:
• Prescription (high risk) registered medicines are available
on prescription only.
• Examples all injectables such as insulin for diabetics
2704/28/16 SAGAR SAVALE
REGISTRATION OF PRISCRIPTION MEDICINES: CATEGORY 1ST
AND 2ND
GO VIA FOLLOWING PATH.
04/28/16 SAGAR SAVALE 28
Therapeutic Claims
• Both registered and listed medicines can carry therapeutic
claims.There are three levels of therapeutic claims - high,
medium and general.
• High level claims are the strongest claims such as treating,
curing, managing or preventing a disease or disorder, or
treating vitamin or mineral deficiency diseases.
• Medium level claims are lesser claims such as health
enhancement claim
• General level claims are the broadest claims such as health
maintenance claims
• Registered medicines are allowed to carry all three levels of
therapeutic claims. Listed medicines are allowed to carry
medium or general levels of therapeutic claims
2904/28/16 SAGAR SAVALE
Complementary medicines
• Complementary medicines also known as 'traditional' or
'alternative' medicines Complementary medicines are low risk
medicines which include herbal medicines, vitamins,
nutritional supplements, aromatherapy ,homoeopathic and
naturopathic products.
• Complementary medicines may be either listed or registered,
depending on their ingredients and the claims made.
• The Therapeutic Goods Act 1989 requires that complementary
medicines which are imported or manufactured for supply in
Australia must be included in the Australian Register of
Therapeutic Goods (ARTG).
• Sponsors of low risk products which carry general or medium
levels claims are required to apply for the listing of the
products in the Australian Register of Therapeutic Goods.
3004/28/16 SAGAR SAVALE
• However, if the sponsors wish to make claims about the
efficacy of the low risk products, they must apply for the
registration (not listing) of the products in the ARTG.
• Registered products are evaluated for safety, quality and
efficacy before they are made available for supply in
Australia..
• All complementary medicines supplied in Australia are
required to comply with the Code of GMP. The Code of GMP
describes the principles and practices that are necessary to
follow in order to provide assurance that each
complementary medicine product is safe and reliable. Most
complementary medicines are widely available through direct
marketing, health food stores and supermarkets.
3104/28/16 SAGAR SAVALE
REGISTRATION OF COMPLEMENTORY MEDICINES
04/28/16 SAGAR SAVALE 32
REGISTRATION OF OTC MEDICINES
04/28/16 SAGAR SAVALE 33
Buying medicines - What's on the label for me?
• Labelling is part of the national system of regulating medicines. Most of
these products must be included in the Australian Register of Therapeutic
Goods. Labeling of medicines is governed under the Therapeutic Goods
Act 1989
• Apart from the general information such as name, quantity, and dosage
of medicines, etc., which must be included in the labels, all medicines are
required to carry either the "Aust R" or "Aust L" labels which indicate
whether or not the efficacy of the products have been evaluated.
What do the Aust R and Aust L numbers mean?
• AUST R medicines are assessed for safety, quality and effectiveness. They
include all prescription only medicines and many over-the-counter
products such as those for pain relief, coughs and colds and antiseptic
creams.
• Prescription only medicines do not display their purpose on the label as
the decision for using them lies with a doctor
• AUST L medicines are much lower risk self-medication products. They are
used for minor health problems and are reviewed for safety and quality.
They include sunscreens over and many vitamin, mineral, herbal and
homoeopathic products.
3404/28/16 SAGAR SAVALE
Always read the labels on medicines
– Check to see if there is an AUST R or AUST L number
– Unless it has been prescribed by a doctor, check the medicine's uses to make sure they are
suitable for your needs.
– Read carefully all directions and warnings, and always follow them.
– Check the storage conditions including the recommended temperature.
– Check the expiry date. When the date is reached, safely dispose of any remaining medicine.
– See if the batch number and supplier's name and address are visible.
3504/28/16 SAGAR SAVALE
• A label is written, printed or graphic matter on or attached to a
container to identify its contents and inform the consumer about its
qualities, uses and hazards
• Contrast and colours
• As some people have poor sight or colour blindness and the label may
have to be read under poorly lighted conditions, particular attention
should be given to colour constrast.
• Letter height
• Approval will not be given for the use of letters less than 1mm.
• Language Labels must be written in English
• Signal Words
• The SUSDP requires specific signal words to be placed at the top of the
main (front) label of drugs and poisons.
3604/28/16 SAGAR SAVALE
These signal words indicate either the restriction applying to the drug or
poison or the relative danger of the product.
Schedule Signal Words
2 -PHARMACY MEDICINE
3 -PHARMACIST ONLY MEDICINE
4 - PRESCRIPTION ONLY MEDICINE
5 - CAUTION
6 - POISON
7 - DANGEROUS POISON
8 - CONTROLLED DRUG
3704/28/16 SAGAR SAVALE
Standard for the Uniform Scheduling of
Drugs and Poisons(SUSDP)
Scheduling is a national classification system that
controls how medicines and chemicals are made
available to the public. Medicines and chemicals are
classified into Schedules according to the level of
regulatory control over the medicine or chemical,
required to protect public health and safety. The
Schedules are-
• Schedule 1 Not currently in use
• Schedule 2 Pharmacy Medicine
• Schedule 3 Pharmacist Only Medicine
• Schedule 4 Prescription Only Medicine
• Schedule 5 Caution
• Schedule 6 Poison 3804/28/16 SAGAR SAVALE
• Schedule 7 Dangerous Poison
• Schedule 8 Controlled Drug
• Schedule 9 Prohibited Substance
• The Schedules are published in the Standard for the
Uniform Scheduling of Drugs and Poisons (SUSDP) .
• The SUSDP lists all the substances, their classifications,
labeling and packaging requirements. The classification
takes into account a substance's toxicity profile, pattern
of use, indications, product formulation and dosage,
potential for abuse and need for access.
• The table below shows some examples:
3904/28/16 SAGAR SAVALE
SCHEDULE DISCRIPTION EXAMPLE
2(S2) Pharmacy medicine Non-prescription medicine
sold in pharmacies.
Pharmacist advice require for
safe use.
Daily use of 1200 mg or less of
ibuprofen in preparation for
oral use.
3(S3)Pharmacist only medicine Non-prescription medicine for
supply by pharmacist only.
Aerosol inhaler contain 100
mcg salbutamol
4(S4) Prescription only
medicine
prescription only medicine for
supply by pharmacist only.
vaccines
5(S5)Caution Substance with low potential
cause harm. appropriated
labeling and packaging can
reduce the extent of harm
Turpentine oil in preparation
mainly contain more than 75%
turpentine oil.
6(S6) Poison Substance with moderate
potential to cause harm, the
use of distinctive packaging
with strong warning and
safety on label can reduce
extent of harm
Sulphuric acid except in fire
extinguisher or preparation
containing 0.5% or less of
Sulphuric acid.
04/28/16 SAGAR SAVALE 40
SCHEDULE DISCRIPTION EXAMPLE
7(S7) Dangerous poison Substance with high potential
to cause harm, at low expose
and require special precaution
during manufacturing,
handling for use.
Cyanides except ferricynide,
ferrocyanide or if specified in
other schedule
8(S8) Controlled drug Sub. Which require restriction
of manufacture, supply,
distribution, possession and
use to reduce abuse, misuse
and physical and physiological
dependence.
Methadone, morphine
9(S9) Prohibited sub. Sub. Which may abuse or
misuse, the illegal possession,
use, sale should be prohibited
by law.
Heroine, coca leaf
04/28/16 SAGAR SAVALE 41
04/28/16 SAGAR SAVALE 42
• Counterfeit medicines or medical devices are often
packaged or marketed to mimic a genuine item. Products
are considered counterfeit if the labeling, presentation,
advertising, formulation or source of the goods is false.
Counterfeiting can apply to both branded (originator) and
generic products.
• The TGA, with cooperation from State and Territory
Governments, closely monitors the supply chain in
Australia to prevent counterfeit medicines or medical
devices from entering the market.
• Consumers can also suffer harm from leaving a serious
medical condition untreated or inappropriately treated.
• All therapeutic goods are potential targets for
counterfeiters.
4304/28/16 SAGAR SAVALE
• Examples of counterfeit medical products can range from
widely used medicines such as paracetamol, through to
limited use medicines such as cancer and heart medicine.
Medical devices, such as contact lenses, condoms, blood
glucose test strips and surgical mesh are also subject to
counterfeiting.
• Counterfeit products detected in Australia are generally
lifestyle medicines – such as weight loss, hair loss and
erectile dysfunction medicines.
• Most of the counterfeit products that enter the country are
imported mistakenly in small quantities for personal use by
individuals making a purchase via the Internet, or by
travellers who made the purchase while travelling
overseas.
• To avoid purchasing counterfeit products, consumers
should exercise caution when buying medicines on the 4404/28/16 SAGAR SAVALE
• The Internet can offer consumers a convenient way to access
therapeutic goods, but online purchases of medicines or
devices should be approached with caution.
• Do not order medicines, including dietary supplements and
herbal preparations, over the Internet unless you know
exactly what is in the preparation and have checked the legal
requirements for importation and use in Australia.
• Consumers are again advised to exercise extreme caution
about purchasing medicines from unknown internet sites.
Products purchased in this way may not meet the same
standards of quality, safety and efficacy as those approved by
the TGA for supply in Australia, and may contain undisclosed
and potentially harmful ingredients.
• The Therapeutic Goods Administration (TGA) is aware that
some Australian consumers have purchased the
product SATURO capsules over the internet. The label of this
product claims the ingredients to be 100% herbal in origin.
4504/28/16 SAGAR SAVALE
• However, analysis undertaken by the TGA Laboratories in
Australia has confirmed the presence of therapeutic quantities
of Sildenafil in these capsules. Sildenafil is the active ingredient
in the approved Pfizer Australia Pty Ltd product Viagra.
• Consumers are advised that Sildenafil is a prescription-only
medicine in Australia, and may be harmful if taken without the
supervision of a medical professional, particularly in patients
with history of cardiovascular disease.
• SATURO capsules have not been assessed
by the TGA for quality, safety or efficacy
as required under Australian legislation,
and the place of manufacture is not
approved by the TGA. In Australia,
commercial supply of SATURO capsules is illegal.
4604/28/16 SAGAR SAVALE
1 sur 46

Recommandé

THERAPEUTIC GOODS ADMINISTRATION (TGA) and MHRA par
THERAPEUTIC GOODS ADMINISTRATION (TGA) and MHRATHERAPEUTIC GOODS ADMINISTRATION (TGA) and MHRA
THERAPEUTIC GOODS ADMINISTRATION (TGA) and MHRAManikant Prasad Shah
11.5K vues58 diapositives
INDA/NDA/ANDA par
INDA/NDA/ANDAINDA/NDA/ANDA
INDA/NDA/ANDARohit Bhosale
27.1K vues43 diapositives
Ctd and e ctd par
Ctd and e ctdCtd and e ctd
Ctd and e ctdBashant Kumar sah
11K vues16 diapositives
Regulatory requirement for approval of Biologics par
Regulatory requirement for approval of BiologicsRegulatory requirement for approval of Biologics
Regulatory requirement for approval of BiologicsArpitha Aarushi
17.8K vues36 diapositives
Hatch waxman act & amendments ppt par
Hatch waxman act & amendments  pptHatch waxman act & amendments  ppt
Hatch waxman act & amendments pptAlexa Jacob
40.7K vues30 diapositives
Regulatory requirement for europe union par
Regulatory requirement for europe unionRegulatory requirement for europe union
Regulatory requirement for europe unionShresthaPandey1
8.7K vues19 diapositives

Contenu connexe

Tendances

Drug master file par
Drug master fileDrug master file
Drug master fileVrushaliSonar
17.8K vues22 diapositives
The introduction of an orange book par
The introduction of an orange bookThe introduction of an orange book
The introduction of an orange bookindus university-icri
9.5K vues10 diapositives
Orange book par
Orange bookOrange book
Orange bookRucha Pathak
28.5K vues42 diapositives
Generic drug product development par
Generic drug product developmentGeneric drug product development
Generic drug product developmentBashant Kumar sah
26.9K vues18 diapositives
Regulatory guidelines of Australia par
Regulatory guidelines of AustraliaRegulatory guidelines of Australia
Regulatory guidelines of Australianandiniwarier93
7.1K vues33 diapositives
ANDA regulatory approval process par
ANDA regulatory approval processANDA regulatory approval process
ANDA regulatory approval processROHIT
18.7K vues35 diapositives

Tendances(20)

Regulatory guidelines of Australia par nandiniwarier93
Regulatory guidelines of AustraliaRegulatory guidelines of Australia
Regulatory guidelines of Australia
nandiniwarier937.1K vues
ANDA regulatory approval process par ROHIT
ANDA regulatory approval processANDA regulatory approval process
ANDA regulatory approval process
ROHIT 18.7K vues
Global Subbmission of IND, NDA, ANDA par Maruthi.N
Global Subbmission of IND, NDA, ANDA Global Subbmission of IND, NDA, ANDA
Global Subbmission of IND, NDA, ANDA
Maruthi.N 41.8K vues
Regulatory requirement of EU, MHRA and TGA par Himal Barakoti
Regulatory requirement of EU, MHRA and TGARegulatory requirement of EU, MHRA and TGA
Regulatory requirement of EU, MHRA and TGA
Himal Barakoti35.9K vues
Code of federal regulations {cfr} in pharmaceutical par Arabinda Changmai
Code of federal regulations {cfr} in pharmaceuticalCode of federal regulations {cfr} in pharmaceutical
Code of federal regulations {cfr} in pharmaceutical
Arabinda Changmai16.6K vues
overview of Japan pharmaceutical regulatory authority - PMDA par Nandhanan
overview of Japan  pharmaceutical regulatory authority - PMDAoverview of Japan  pharmaceutical regulatory authority - PMDA
overview of Japan pharmaceutical regulatory authority - PMDA
Nandhanan7.4K vues
New Drug Application [NDA] par Sagar Savale
New Drug Application [NDA]New Drug Application [NDA]
New Drug Application [NDA]
Sagar Savale114.4K vues

Similaire à Therapeutic good administration

therapeuticgoodadministration.pdf par
therapeuticgoodadministration.pdftherapeuticgoodadministration.pdf
therapeuticgoodadministration.pdfSanjiv Pandey
3 vues46 diapositives
TGA, MHRA, MCC, MCA par
TGA, MHRA, MCC, MCATGA, MHRA, MCC, MCA
TGA, MHRA, MCC, MCASagar Savale
35.1K vues36 diapositives
Therapeutic Good Administration par
Therapeutic Good AdministrationTherapeutic Good Administration
Therapeutic Good AdministrationSAKSHI YADAV
714 vues13 diapositives
Regulatory of australia par
Regulatory of australiaRegulatory of australia
Regulatory of australiaPradeep Gusain
480 vues43 diapositives
Therapeutic goods administration par
Therapeutic goods administrationTherapeutic goods administration
Therapeutic goods administrationSalwa Hussain
254 vues42 diapositives
Regulatory Authorities for Pharmaceuticals - TGA,MHRA,MCC par
Regulatory Authorities for Pharmaceuticals - TGA,MHRA,MCCRegulatory Authorities for Pharmaceuticals - TGA,MHRA,MCC
Regulatory Authorities for Pharmaceuticals - TGA,MHRA,MCCSanket Shinde
435 vues33 diapositives

Similaire à Therapeutic good administration(20)

TGA, MHRA, MCC, MCA par Sagar Savale
TGA, MHRA, MCC, MCATGA, MHRA, MCC, MCA
TGA, MHRA, MCC, MCA
Sagar Savale35.1K vues
Therapeutic Good Administration par SAKSHI YADAV
Therapeutic Good AdministrationTherapeutic Good Administration
Therapeutic Good Administration
SAKSHI YADAV714 vues
Therapeutic goods administration par Salwa Hussain
Therapeutic goods administrationTherapeutic goods administration
Therapeutic goods administration
Salwa Hussain254 vues
Regulatory Authorities for Pharmaceuticals - TGA,MHRA,MCC par Sanket Shinde
Regulatory Authorities for Pharmaceuticals - TGA,MHRA,MCCRegulatory Authorities for Pharmaceuticals - TGA,MHRA,MCC
Regulatory Authorities for Pharmaceuticals - TGA,MHRA,MCC
Sanket Shinde435 vues
Events presentations-pac-141010 par TGA Australia
Events presentations-pac-141010Events presentations-pac-141010
Events presentations-pac-141010
TGA Australia1.4K vues
TGA REGULATORY AFFAIRS.pptx par KeerthanaN20
TGA REGULATORY AFFAIRS.pptxTGA REGULATORY AFFAIRS.pptx
TGA REGULATORY AFFAIRS.pptx
KeerthanaN20531 vues
Therapeutics goods administration & Row Countries par Maan Singh
Therapeutics goods administration & Row CountriesTherapeutics goods administration & Row Countries
Therapeutics goods administration & Row Countries
Maan Singh3.4K vues
An introduction to the work of Australia's regulator of therapeutic goods par TGA Australia
An introduction to the work of Australia's regulator of therapeutic goodsAn introduction to the work of Australia's regulator of therapeutic goods
An introduction to the work of Australia's regulator of therapeutic goods
TGA Australia13.7K vues
Clinical trials - TGA role par TGA Australia
Clinical trials - TGA roleClinical trials - TGA role
Clinical trials - TGA role
TGA Australia2.5K vues
TGA presentation: Postmarket Monitoring par TGA Australia
TGA presentation: Postmarket MonitoringTGA presentation: Postmarket Monitoring
TGA presentation: Postmarket Monitoring
TGA Australia8.8K vues
Pharmacovigilance in Australia par Saeeda Hasan
Pharmacovigilance in AustraliaPharmacovigilance in Australia
Pharmacovigilance in Australia
Saeeda Hasan243 vues

Plus de Sagar Savale

Scale up and Post Approval Chenges (SUPAC).pdf par
Scale up and Post Approval Chenges (SUPAC).pdfScale up and Post Approval Chenges (SUPAC).pdf
Scale up and Post Approval Chenges (SUPAC).pdfSagar Savale
91 vues15 diapositives
Sagar K Savale _ Publons.pdf par
Sagar K Savale _ Publons.pdfSagar K Savale _ Publons.pdf
Sagar K Savale _ Publons.pdfSagar Savale
348 vues2 diapositives
Omicron covid variant: a short overview par
Omicron covid variant: a short overviewOmicron covid variant: a short overview
Omicron covid variant: a short overviewSagar Savale
3.7K vues3 diapositives
LinkedIn Certificate par
LinkedIn Certificate LinkedIn Certificate
LinkedIn Certificate Sagar Savale
994 vues1 diapositive
LinkedIn Certificate par
LinkedIn Certificate LinkedIn Certificate
LinkedIn Certificate Sagar Savale
265 vues1 diapositive
LinkedIn Certificate par
LinkedIn Certificate LinkedIn Certificate
LinkedIn Certificate Sagar Savale
294 vues1 diapositive

Plus de Sagar Savale(20)

Scale up and Post Approval Chenges (SUPAC).pdf par Sagar Savale
Scale up and Post Approval Chenges (SUPAC).pdfScale up and Post Approval Chenges (SUPAC).pdf
Scale up and Post Approval Chenges (SUPAC).pdf
Sagar Savale91 vues
Sagar K Savale _ Publons.pdf par Sagar Savale
Sagar K Savale _ Publons.pdfSagar K Savale _ Publons.pdf
Sagar K Savale _ Publons.pdf
Sagar Savale348 vues
Omicron covid variant: a short overview par Sagar Savale
Omicron covid variant: a short overviewOmicron covid variant: a short overview
Omicron covid variant: a short overview
Sagar Savale3.7K vues
E - certificate ijsrem.com sagar kishor savale par Sagar Savale
E - certificate ijsrem.com sagar kishor savaleE - certificate ijsrem.com sagar kishor savale
E - certificate ijsrem.com sagar kishor savale
Sagar Savale211 vues
Certificate of completion time management fundamentals with microsoft office par Sagar Savale
Certificate of completion time management fundamentals with microsoft officeCertificate of completion time management fundamentals with microsoft office
Certificate of completion time management fundamentals with microsoft office
Sagar Savale365 vues
Certificate of completion the data science of healthcare, medicine, and publi... par Sagar Savale
Certificate of completion the data science of healthcare, medicine, and publi...Certificate of completion the data science of healthcare, medicine, and publi...
Certificate of completion the data science of healthcare, medicine, and publi...
Sagar Savale866 vues
Certificate of completion microsoft project quick tips par Sagar Savale
Certificate of completion microsoft project quick tipsCertificate of completion microsoft project quick tips
Certificate of completion microsoft project quick tips
Sagar Savale54 vues
Certificate of completion improving your judgment for better decision-making par Sagar Savale
Certificate of completion improving your judgment for better decision-makingCertificate of completion improving your judgment for better decision-making
Certificate of completion improving your judgment for better decision-making
Sagar Savale31 vues
Certificate of completion data visualization_ best practices par Sagar Savale
Certificate of completion data visualization_ best practicesCertificate of completion data visualization_ best practices
Certificate of completion data visualization_ best practices
Sagar Savale56 vues
Write abstract-improve-article-certificate par Sagar Savale
Write abstract-improve-article-certificateWrite abstract-improve-article-certificate
Write abstract-improve-article-certificate
Sagar Savale42 vues

Dernier

PSI InternetPacketAllFormsJanuary2023.pdf par
PSI InternetPacketAllFormsJanuary2023.pdfPSI InternetPacketAllFormsJanuary2023.pdf
PSI InternetPacketAllFormsJanuary2023.pdfTodd Spodek
8 vues48 diapositives
Three California Courts that Hear Family Matter Cases par
Three California Courts that Hear Family Matter CasesThree California Courts that Hear Family Matter Cases
Three California Courts that Hear Family Matter CasesTerry Chucas
6 vues5 diapositives
VIETNAM - FORMER ENEMY TO STRATEGIC PARTNER OF THE U.S. par
VIETNAM - FORMER ENEMY TO STRATEGIC PARTNER OF THE U.S.VIETNAM - FORMER ENEMY TO STRATEGIC PARTNER OF THE U.S.
VIETNAM - FORMER ENEMY TO STRATEGIC PARTNER OF THE U.S.Dr. Oliver Massmann
6 vues3 diapositives
Innovator Visa UK Cost par
Innovator Visa UK CostInnovator Visa UK Cost
Innovator Visa UK CosteLHRConsultant
13 vues1 diapositive
Kruse Law.pdf par
Kruse Law.pdfKruse Law.pdf
Kruse Law.pdfKruse Law
6 vues4 diapositives
Senate Bill 232 Timeline and Information Sheet par
Senate Bill 232 Timeline and Information SheetSenate Bill 232 Timeline and Information Sheet
Senate Bill 232 Timeline and Information Sheetaddie42
11 vues2 diapositives

Dernier(9)

PSI InternetPacketAllFormsJanuary2023.pdf par Todd Spodek
PSI InternetPacketAllFormsJanuary2023.pdfPSI InternetPacketAllFormsJanuary2023.pdf
PSI InternetPacketAllFormsJanuary2023.pdf
Todd Spodek8 vues
Three California Courts that Hear Family Matter Cases par Terry Chucas
Three California Courts that Hear Family Matter CasesThree California Courts that Hear Family Matter Cases
Three California Courts that Hear Family Matter Cases
Terry Chucas6 vues
Senate Bill 232 Timeline and Information Sheet par addie42
Senate Bill 232 Timeline and Information SheetSenate Bill 232 Timeline and Information Sheet
Senate Bill 232 Timeline and Information Sheet
addie4211 vues
الازمة الروسية الاوكرانية على ضوء نظريات العلاقات الدولية.pdf par mboubouche
الازمة الروسية الاوكرانية على ضوء نظريات العلاقات الدولية.pdfالازمة الروسية الاوكرانية على ضوء نظريات العلاقات الدولية.pdf
الازمة الروسية الاوكرانية على ضوء نظريات العلاقات الدولية.pdf
mboubouche8 vues

Therapeutic good administration

  • 1. Therapeutic Good Administration Australia [TGA] 1 Mr. Sagar Kishor SavaleMr. Sagar Kishor Savale Department of Pharmaceutics avengersagar16@gmail.com 2015-016 Department of Pharmacy (Pharmaceutics)Department of Pharmacy (Pharmaceutics) || Sagar savaleSagar savale 04/28/16 SAGAR SAVALE
  • 2. CONTENTS:  HISTORY  TGA STRUCTURE  THERAPEUTIC GOODS ACT 1989  REGULATION OF MEDICINE  AUSTRELIAN REGISTER FOR THERAPEUTIC GOOD  REGISTRATION OF MEDICINE  THERAPEUTIC CLAIMS  STANDARD FOR THE UNIFORM SCHDULING OF DRUG & POISONS  COUNTERFEIT DRUGS 204/28/16 SAGAR SAVALE
  • 3. HISTORY- The Evolution of Therapeutic goods Administration in Australia can be broadly segmented into following periods. 1)The period until 1938 -During this period there was an increasing number of medicines appearing in an unregulated market, with many products regarded as ‘quack’ medicine. 2)1939-1961:NHMRC developing a more uniform national approach to labeling and standards need for independent laboratory testing. The government moved to regulate the standards for medicines for good quality. The National Biological Standards Laboratory was established to independently test medicines on the Australian market and regulate their manufacture. 3)1962-1988: Pre-market assessment of quality, safety and efficacy evolved and finally was integrated into National system of integration of therapeutic good regulation and establishment of TGA. 4)1989-2007:The national system TGA continued to mature into an internationally harmonized regulatory system with increasing globalization. 304/28/16 SAGAR SAVALE
  • 4. INTRODUCTION OF TGA: • The Therapeutic Goods Administration (TGA) is a unit of the Australian Government Department of Health and Ageing. • The TGA monitoring activities to ensure therapeutic goods available in Australia are of an acceptable standard. • The Australian community expects that medicines and medical devices in the marketplace are safe and of high quality, and of a standard at least equal to that of comparable countries. • The regulatory framework within which the TGA operates is based on a risk management approach. It is designed to ensure public health and safety. • It is beneficial for both consumers and industry • In undertaking its responsibility, the TGA has developed a constructive partnership with industry at the same time freeing industry from any unnecessary regulatory burden and minimizing the cost of medicines. 404/28/16 SAGAR SAVALE
  • 5. TGA STRUCTRE- • The TGA Regulatory offices are grouped into – 1. Market Authorisation Group 2. Monitoring and Compliance Group 3. Regulatory Support Group • TGA Executive • The TGA Executive has overall responsibility for the management of the TGA's regulatory activities. 1.Market Authorization Group • The Market Authorization Group is responsible for the evaluation and authorization of therapeutic goods to ensure they meet appropriate standards of quality, safety and efficacy. 504/28/16 SAGAR SAVALE
  • 6. 2.Monitoring and Compliance Group- • The Monitoring and Compliance Group is responsible for monitoring of therapeutic goods on the Australian market to ensure that they comply with required standards of quality, safety, efficacy . 3.Regulatory Support Group • The Regulatory Support Group provides the business systems and support services that help the TGA to undertake its regulatory responsibilities. • Office of Regulatory Integrity • The Office of Regulatory Integrity functions as an internal auditor of regulatory activity and advises the TGA Executive on the appropriate operations. 604/28/16 SAGAR SAVALE
  • 7. Therapeutic Goods Act 1989 • Therapeutic Goods Act 1989, is to provide a national framework for the regulation of therapeutic goods in Australia to ensure the Quality, Safety and Efficacy of medicines Ensure the quality, safety and performance of medical devices. • The Act is a Commonwealth Act that provides a uniform national system of controls over therapeutic goods. • facilitating trade between the States/Territories and benefiting for both consumers and industry. • Essentially therapeutic goods must be entered on the Australian Register of Therapeutic Goods (ARTG) before they can be supplied in Australia. • The ARTG is a computer database of information about therapeutic goods for human use approved for supply in, or exported from Australia. 704/28/16 SAGAR SAVALE
  • 8. • It also details the requirements for listing or registering medicines in the Australian Register of Therapeutic Goods. • The act sets out the legal requirement for the import , export, and supply of medicines in Australia. • The Therapeutic Goods Act sets out requirements for manufacturing, advertising and labeling of medicines in Australia. • It also establishes controls relating to the advertising of therapeutic goods which aim to minimize the risk of misuse of such products arising out of, for example, misrepresentation or misunderstanding about the uses of the goods. • It offers the advantage for consumers and healthcare professionals to be able to have confidence in the standard of ready-made proprietary therapeutic goods which they use or prescribe. 804/28/16 SAGAR SAVALE
  • 9. Does the Act apply to your product? You will need to comply with the Act if your product is a 'therapeutic good'. 'Therapeutic goods' may be: • Medicines, or • Medical devices • Some products will be classified as a medicine or as a food or cosmetic depending on how that particular product fits with the criteria set out in the Act. 904/28/16 SAGAR SAVALE
  • 10. What are 'therapeutic goods'? A 'therapeutic good is broadly defined as a good which is represented in any way to be, or is likely to be taken to be, for therapeutic use under section 7 of the Act. • Therapeutic good is a product for use in humans that is used in, or in connection with:- • Preventing, diagnosing, curing a disease, defect or injury OR • Influencing, inhibiting or modifying a physiological process OR • Testing the susceptibility of persons to a disease OR • Influencing, controlling or preventing conception OR • Testing for pregnancy 1004/28/16 SAGAR SAVALE
  • 11. Is it a medicine or food? • Products for oral consumption are regulated as either foods or therapeutic goods • Products which may fit within the definition of either a food or a medicine are referred to a joint TGA/Food Standards Australia committee which recommends whether the goods should be regulated as a therapeutic good or as food • A product's principal use is of primary consideration when determining whether it is a food or a medicine • The presentation of a product can help to determine whether it will be treated as a food or a medicine. For example, a clove of garlic is a food. However, if it is concentrated and marketed in capsule form with claims that it can be used to relieve cold and 'flu symptoms it will be treated as a medicine 1104/28/16 SAGAR SAVALE
  • 12. Is it a medicine or a cosmetic? • One of the main factors in determining whether a product is a cosmetic or a medicine is the claims made about the product. • For example, moisturizers which contain a sun screening agent as a secondary component and have a stated therapeutic purpose (e.g. 'helps protect skin from the damaging effects of UV radiation') are medicine • Note that the Trade Practices Act 1974 also operates in this area and influences what may or may not be claimed. • The Cosmetic Claims Guidelines provides further guidance on the difference between cosmetic and therapeutic claims 1204/28/16 SAGAR SAVALE
  • 13. Regulation of Medicines • The Therapeutic Goods Administration overall control the of supply of medicines in Australia is exercised through following main processes: • 1. Pre-market evaluation and approval of medicines intended for supply in Australia • 2. Licensing of manufacturers in accordance with international standards under Good Manufacturing Practice • 3. Post-market monitoring, through sampling, adverse event reporting, surveillance activities, and response to public inquiries • 4. maintenance and monitoring of the systems for registering and listing of medicines 1304/28/16 SAGAR SAVALE
  • 14. Pre-Market Assessment- • Drugs are required to undergo an assessment before it can be listed or registered. • Number of factors are taken into consideration including: • The toxicity of the ingredients. • The dosage form of the medicine • whether the medicine is indicated for a serious form of a disease, or disorder, or for the treatment, cure, prevention of a disease or disorder • whether the drug is likely to result in significant side effects, including interactions with other medicines; and • The degree of control over a medicine is directly related to the risk level of that medicine. Therefore, registered medicines are required to undergo a more rigorous assessment than listed medicines 1404/28/16 SAGAR SAVALE
  • 15. • Manufacturing Requirements- Australian manufacturers of medicines must be licensed under the Therapeutic Goods Act 1989. Their manufacturing processes must comply with principles of Good Manufacturing Practice. The aim of licensing is to protect public health by ensuring that medicines meet definable standards of quality assurance and are manufactured in conditions which are clean and free of contaminants. • Licensing of Manufacturers Applications for a manufacturing license are assessed through an inspection of the manufacturing premises. Auditors from the TGA conduct audits of manufacturing premises and a license is issued only after all the requirements have been met. Audits are conducted before a license is issued, And at regular intervals after the license has been granted generally every 15 to 24 months. 1504/28/16 SAGAR SAVALE
  • 16. Post-Market Vigilance- In Australia, post-market vigilance activities include the following: • Conducting laboratory testing of products on the market and if necessary, conducting recalls of deficient medicines. • According to the TGA, these activities are conducted regularly and in response to problem reports received. • Adverse Drug Event Reporting- The Adverse Drug Reactions Advisory Committee(ADRAC) is responsible for monitoring drug safety in the post-marketing phase. • This involves checking the report of adverse reaction of the drug, investigating problems by the Therapeutic Goods Administration and relevant committees to ensure that medicines are of an acceptable standard. 1604/28/16 SAGAR SAVALE
  • 17. • Making the decision as to whether further information such as clinical or laboratory testing results are required. • The reports are then entered into a database and reviewed by the ADRAC which would provide advice on the appropriate responses to adverse reactions such as a recall of deficient medicines to the relevant authorities e.g. Australian Drug Evaluation Committee for pharmaceutical products, Medicines Evaluation Committee for over-the- counter medicines, Office of Complementary Medicines of the T G A for complementary medicines, etc. • Recall of Medicines- • A recall is a permanent removal of deficient medicines from the market. Most recalls are conducted on a voluntary basis. However, the recall procedures are carried by Therapeutic Goods Act 1989 and the Trade Practices Act 1974. 1704/28/16 SAGAR SAVALE
  • 18. • There are four levels of recall: wholesale, hospital, retail and consumer. • A wholesale level refers to a recall from state purchasing authorities. • A hospital level recall includes a whole sale level recall and recalls from nursing homes, hospital pharmacies, etc. • A retail level recall includes a wholesale level recall, a hospital level recall and recalls from retail pharmacists, medical practitioners, retail outlets, etc. • A consumer level recall includes a whole sale level recall, a hospital level recall, a retail level recall and recalls from patients and other consumers. 1804/28/16 SAGAR SAVALE
  • 19. REGULATION OF MEDICINE IN AUSTRELIA In Australia, medicines can be classified as 1) Registered medicines or 2) Listed medicines, depending on their ingredients and claims made. Registered medicines can be further classified as- 1)Non-prescription (low risk) registered medicines and as 2) Prescription (high risk) registered medicines. All medicines which are for export only are considered as listed medicines. • Registered medicines are of higher risk than listed medicines, therefore, the degree of control imposed on registered medicines is higher than that of listed medicines; • Registered medicines are evaluated for safety, quality and efficacy while listed medicines are evaluated for safety and quality only. 1904/28/16 SAGAR SAVALE
  • 21. • Austrelian Register for Therapeutic Good • The Australian Register of Therapeutic Goods is a database of information about therapeutic goods which are approved for supply in or export from Australia. • Registered medicines in the Australian Register of Therapeutic Goods are of higher risk than listed medicines. • Therefore the level of assessment and the degree of regulation which registered medicines undergo are also more rigorous and detailed. • The sponsors of registered medicines are required to provide comprehensive safety, quality and efficacy data. • sponsors of listed medicines are required to provide data on safety and quality only. • Diagram shows the risk relationship between the various types of medicines registered or listed in the ARTG. 2104/28/16 SAGAR SAVALE
  • 23. Listed Medicines (low-risk)- • A listed medicine is one that contains chemical, biological, or herbal ingredients that are well-known and considered safe to the user such ingredients usually have a long history of use. • They are considered as low-risk, their ingredients appear in the TGA’s approved list of substances. • Listed medicines do not contain substances which are scheduled in the Standard for Uniform Scheduling of Drugs and Poisons. • The therapeutic claim of medicine relates to health maintenance, health enhancement, or non-serious, self-limiting conditions. • Listed medicines are assessed by the TGA for quality and safety but not efficacy. This means that the TGA has not evaluated them individually to see if they work. 2304/28/16 SAGAR SAVALE
  • 24. • Listed medicines are low risk medicines and they may only contain ingredients which are listed in the Australian Register of Therapeutic Goods. • For the evaluation process, sponsors are allowed to self- assess the products, i.e. the products are assessed by sponsors against standards defined by the Therapeutic Goods Administration. • The assessment is then subject to a simple 'eligibility review' by the Therapeutic Goods Administration for compliance with certain basic safety and quality parameters. • If the assessment passes the 'eligibility review', the sponsor receives a confirmation letter from the Therapeutic Goods Administration and the medicine can be listed in the Australian Register of Therapeutic Goods 2404/28/16 SAGAR SAVALE
  • 25. LISTING OF MEDICINE IN ARTG 04/28/16 SAGAR SAVALE 25
  • 26. REGISTERED MEDICINE • Registered medicines can be high risk products or low risk products. • They can be classified either as non-prescription (low risk) registered medicines or as prescription (high risk) registered medicines. • Medicines having a higher level of risk must be registered (not listed). • The degree of assessment and regulation they undergo is rigorous and detailed, with sponsors being required to provide comprehensive safety, quality and efficacy data. • All registered medicines must display an AUST R number on the label as proof of registration are evaluated as either 'high risk' or 'low risk' registered 2604/28/16 SAGAR SAVALE
  • 27. • In assessing the level of 'risk', factors such as the strength of a product, side effects, potential harm through prolonged use, toxicity, and the seriousness of the medical condition for which the product is intended to be used are taken into account. Non-Prescription (Low Risk) Registered Medicines: • The purchase of non-prescription (low risk) registered medicines does not require a doctor's prescription. Examples of non-prescription (low risk) registered medicines are over-the-counter medicines such as analgesics, cough/cold preparations. Prescription (High Risk) Registered Medicines: • Prescription (high risk) registered medicines are available on prescription only. • Examples all injectables such as insulin for diabetics 2704/28/16 SAGAR SAVALE
  • 28. REGISTRATION OF PRISCRIPTION MEDICINES: CATEGORY 1ST AND 2ND GO VIA FOLLOWING PATH. 04/28/16 SAGAR SAVALE 28
  • 29. Therapeutic Claims • Both registered and listed medicines can carry therapeutic claims.There are three levels of therapeutic claims - high, medium and general. • High level claims are the strongest claims such as treating, curing, managing or preventing a disease or disorder, or treating vitamin or mineral deficiency diseases. • Medium level claims are lesser claims such as health enhancement claim • General level claims are the broadest claims such as health maintenance claims • Registered medicines are allowed to carry all three levels of therapeutic claims. Listed medicines are allowed to carry medium or general levels of therapeutic claims 2904/28/16 SAGAR SAVALE
  • 30. Complementary medicines • Complementary medicines also known as 'traditional' or 'alternative' medicines Complementary medicines are low risk medicines which include herbal medicines, vitamins, nutritional supplements, aromatherapy ,homoeopathic and naturopathic products. • Complementary medicines may be either listed or registered, depending on their ingredients and the claims made. • The Therapeutic Goods Act 1989 requires that complementary medicines which are imported or manufactured for supply in Australia must be included in the Australian Register of Therapeutic Goods (ARTG). • Sponsors of low risk products which carry general or medium levels claims are required to apply for the listing of the products in the Australian Register of Therapeutic Goods. 3004/28/16 SAGAR SAVALE
  • 31. • However, if the sponsors wish to make claims about the efficacy of the low risk products, they must apply for the registration (not listing) of the products in the ARTG. • Registered products are evaluated for safety, quality and efficacy before they are made available for supply in Australia.. • All complementary medicines supplied in Australia are required to comply with the Code of GMP. The Code of GMP describes the principles and practices that are necessary to follow in order to provide assurance that each complementary medicine product is safe and reliable. Most complementary medicines are widely available through direct marketing, health food stores and supermarkets. 3104/28/16 SAGAR SAVALE
  • 32. REGISTRATION OF COMPLEMENTORY MEDICINES 04/28/16 SAGAR SAVALE 32
  • 33. REGISTRATION OF OTC MEDICINES 04/28/16 SAGAR SAVALE 33
  • 34. Buying medicines - What's on the label for me? • Labelling is part of the national system of regulating medicines. Most of these products must be included in the Australian Register of Therapeutic Goods. Labeling of medicines is governed under the Therapeutic Goods Act 1989 • Apart from the general information such as name, quantity, and dosage of medicines, etc., which must be included in the labels, all medicines are required to carry either the "Aust R" or "Aust L" labels which indicate whether or not the efficacy of the products have been evaluated. What do the Aust R and Aust L numbers mean? • AUST R medicines are assessed for safety, quality and effectiveness. They include all prescription only medicines and many over-the-counter products such as those for pain relief, coughs and colds and antiseptic creams. • Prescription only medicines do not display their purpose on the label as the decision for using them lies with a doctor • AUST L medicines are much lower risk self-medication products. They are used for minor health problems and are reviewed for safety and quality. They include sunscreens over and many vitamin, mineral, herbal and homoeopathic products. 3404/28/16 SAGAR SAVALE
  • 35. Always read the labels on medicines – Check to see if there is an AUST R or AUST L number – Unless it has been prescribed by a doctor, check the medicine's uses to make sure they are suitable for your needs. – Read carefully all directions and warnings, and always follow them. – Check the storage conditions including the recommended temperature. – Check the expiry date. When the date is reached, safely dispose of any remaining medicine. – See if the batch number and supplier's name and address are visible. 3504/28/16 SAGAR SAVALE
  • 36. • A label is written, printed or graphic matter on or attached to a container to identify its contents and inform the consumer about its qualities, uses and hazards • Contrast and colours • As some people have poor sight or colour blindness and the label may have to be read under poorly lighted conditions, particular attention should be given to colour constrast. • Letter height • Approval will not be given for the use of letters less than 1mm. • Language Labels must be written in English • Signal Words • The SUSDP requires specific signal words to be placed at the top of the main (front) label of drugs and poisons. 3604/28/16 SAGAR SAVALE
  • 37. These signal words indicate either the restriction applying to the drug or poison or the relative danger of the product. Schedule Signal Words 2 -PHARMACY MEDICINE 3 -PHARMACIST ONLY MEDICINE 4 - PRESCRIPTION ONLY MEDICINE 5 - CAUTION 6 - POISON 7 - DANGEROUS POISON 8 - CONTROLLED DRUG 3704/28/16 SAGAR SAVALE
  • 38. Standard for the Uniform Scheduling of Drugs and Poisons(SUSDP) Scheduling is a national classification system that controls how medicines and chemicals are made available to the public. Medicines and chemicals are classified into Schedules according to the level of regulatory control over the medicine or chemical, required to protect public health and safety. The Schedules are- • Schedule 1 Not currently in use • Schedule 2 Pharmacy Medicine • Schedule 3 Pharmacist Only Medicine • Schedule 4 Prescription Only Medicine • Schedule 5 Caution • Schedule 6 Poison 3804/28/16 SAGAR SAVALE
  • 39. • Schedule 7 Dangerous Poison • Schedule 8 Controlled Drug • Schedule 9 Prohibited Substance • The Schedules are published in the Standard for the Uniform Scheduling of Drugs and Poisons (SUSDP) . • The SUSDP lists all the substances, their classifications, labeling and packaging requirements. The classification takes into account a substance's toxicity profile, pattern of use, indications, product formulation and dosage, potential for abuse and need for access. • The table below shows some examples: 3904/28/16 SAGAR SAVALE
  • 40. SCHEDULE DISCRIPTION EXAMPLE 2(S2) Pharmacy medicine Non-prescription medicine sold in pharmacies. Pharmacist advice require for safe use. Daily use of 1200 mg or less of ibuprofen in preparation for oral use. 3(S3)Pharmacist only medicine Non-prescription medicine for supply by pharmacist only. Aerosol inhaler contain 100 mcg salbutamol 4(S4) Prescription only medicine prescription only medicine for supply by pharmacist only. vaccines 5(S5)Caution Substance with low potential cause harm. appropriated labeling and packaging can reduce the extent of harm Turpentine oil in preparation mainly contain more than 75% turpentine oil. 6(S6) Poison Substance with moderate potential to cause harm, the use of distinctive packaging with strong warning and safety on label can reduce extent of harm Sulphuric acid except in fire extinguisher or preparation containing 0.5% or less of Sulphuric acid. 04/28/16 SAGAR SAVALE 40
  • 41. SCHEDULE DISCRIPTION EXAMPLE 7(S7) Dangerous poison Substance with high potential to cause harm, at low expose and require special precaution during manufacturing, handling for use. Cyanides except ferricynide, ferrocyanide or if specified in other schedule 8(S8) Controlled drug Sub. Which require restriction of manufacture, supply, distribution, possession and use to reduce abuse, misuse and physical and physiological dependence. Methadone, morphine 9(S9) Prohibited sub. Sub. Which may abuse or misuse, the illegal possession, use, sale should be prohibited by law. Heroine, coca leaf 04/28/16 SAGAR SAVALE 41
  • 43. • Counterfeit medicines or medical devices are often packaged or marketed to mimic a genuine item. Products are considered counterfeit if the labeling, presentation, advertising, formulation or source of the goods is false. Counterfeiting can apply to both branded (originator) and generic products. • The TGA, with cooperation from State and Territory Governments, closely monitors the supply chain in Australia to prevent counterfeit medicines or medical devices from entering the market. • Consumers can also suffer harm from leaving a serious medical condition untreated or inappropriately treated. • All therapeutic goods are potential targets for counterfeiters. 4304/28/16 SAGAR SAVALE
  • 44. • Examples of counterfeit medical products can range from widely used medicines such as paracetamol, through to limited use medicines such as cancer and heart medicine. Medical devices, such as contact lenses, condoms, blood glucose test strips and surgical mesh are also subject to counterfeiting. • Counterfeit products detected in Australia are generally lifestyle medicines – such as weight loss, hair loss and erectile dysfunction medicines. • Most of the counterfeit products that enter the country are imported mistakenly in small quantities for personal use by individuals making a purchase via the Internet, or by travellers who made the purchase while travelling overseas. • To avoid purchasing counterfeit products, consumers should exercise caution when buying medicines on the 4404/28/16 SAGAR SAVALE
  • 45. • The Internet can offer consumers a convenient way to access therapeutic goods, but online purchases of medicines or devices should be approached with caution. • Do not order medicines, including dietary supplements and herbal preparations, over the Internet unless you know exactly what is in the preparation and have checked the legal requirements for importation and use in Australia. • Consumers are again advised to exercise extreme caution about purchasing medicines from unknown internet sites. Products purchased in this way may not meet the same standards of quality, safety and efficacy as those approved by the TGA for supply in Australia, and may contain undisclosed and potentially harmful ingredients. • The Therapeutic Goods Administration (TGA) is aware that some Australian consumers have purchased the product SATURO capsules over the internet. The label of this product claims the ingredients to be 100% herbal in origin. 4504/28/16 SAGAR SAVALE
  • 46. • However, analysis undertaken by the TGA Laboratories in Australia has confirmed the presence of therapeutic quantities of Sildenafil in these capsules. Sildenafil is the active ingredient in the approved Pfizer Australia Pty Ltd product Viagra. • Consumers are advised that Sildenafil is a prescription-only medicine in Australia, and may be harmful if taken without the supervision of a medical professional, particularly in patients with history of cardiovascular disease. • SATURO capsules have not been assessed by the TGA for quality, safety or efficacy as required under Australian legislation, and the place of manufacture is not approved by the TGA. In Australia, commercial supply of SATURO capsules is illegal. 4604/28/16 SAGAR SAVALE